Tags

Type your tag names separated by a space and hit enter

Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Infect Dis Poverty. 2020 Sep 16; 9(1):132.ID

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) linked with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause severe illness and life-threatening pneumonia in humans. The current COVID-19 pandemic demands an effective vaccine to acquire protection against the infection. Therefore, the present study was aimed to design a multiepitope-based subunit vaccine (MESV) against COVID-19.

METHODS

Structural proteins (Surface glycoprotein, Envelope protein, and Membrane glycoprotein) of SARS-CoV-2 are responsible for its prime functions. Sequences of proteins were downloaded from GenBank and several immunoinformatics coupled with computational approaches were employed to forecast B- and T- cell epitopes from the SARS-CoV-2 highly antigenic structural proteins to design an effective MESV.

RESULTS

Predicted epitopes suggested high antigenicity, conserveness, substantial interactions with the human leukocyte antigen (HLA) binding alleles, and collective global population coverage of 88.40%. Taken together, 276 amino acids long MESV was designed by connecting 3 cytotoxic T lymphocytes (CTL), 6 helper T lymphocyte (HTL) and 4 B-cell epitopes with suitable adjuvant and linkers. The MESV construct was non-allergenic, stable, and highly antigenic. Molecular docking showed a stable and high binding affinity of MESV with human pathogenic toll-like receptors-3 (TLR3). Furthermore, in silico immune simulation revealed significant immunogenic response of MESV. Finally, MEV codons were optimized for its in silico cloning into the Escherichia coli K-12 system, to ensure its increased expression.

CONCLUSION

The MESV developed in this study is capable of generating immune response against COVID-19. Therefore, if designed MESV further investigated experimentally, it would be an effective vaccine candidate against SARS-CoV-2 to control and prevent COVID-19.

Authors+Show Affiliations

College of Life Science and Technology, Guangxi University, Nanning, P. R. China.Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad, Pakistan.Jinnah Hospital, Lahore, Pakistan.Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad, Pakistan. usmancemb@gmail.com.Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad, Pakistan.Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad, Pakistan.Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad, Pakistan.Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan.College of Life Science and Technology, Guangxi University, Nanning, P. R. China. llchen@mail.hzau.edu.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32938504

Citation

Tahir Ul Qamar, Muhammad, et al. "Reverse Vaccinology Assisted Designing of Multiepitope-based Subunit Vaccine Against SARS-CoV-2." Infectious Diseases of Poverty, vol. 9, no. 1, 2020, p. 132.
Tahir Ul Qamar M, Shahid F, Aslam S, et al. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2. Infect Dis Poverty. 2020;9(1):132.
Tahir Ul Qamar, M., Shahid, F., Aslam, S., Ashfaq, U. A., Aslam, S., Fatima, I., Fareed, M. M., Zohaib, A., & Chen, L. L. (2020). Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2. Infectious Diseases of Poverty, 9(1), 132. https://doi.org/10.1186/s40249-020-00752-w
Tahir Ul Qamar M, et al. Reverse Vaccinology Assisted Designing of Multiepitope-based Subunit Vaccine Against SARS-CoV-2. Infect Dis Poverty. 2020 Sep 16;9(1):132. PubMed PMID: 32938504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2. AU - Tahir Ul Qamar,Muhammad, AU - Shahid,Farah, AU - Aslam,Sadia, AU - Ashfaq,Usman Ali, AU - Aslam,Sidra, AU - Fatima,Israr, AU - Fareed,Muhammad Mazhar, AU - Zohaib,Ali, AU - Chen,Ling-Ling, Y1 - 2020/09/16/ PY - 2020/04/29/received PY - 2020/09/08/accepted PY - 2020/9/17/entrez PY - 2020/9/18/pubmed PY - 2020/9/25/medline KW - COVID-19 KW - Epitope KW - Immunoinformatics KW - Multiepitope-based subunit vaccine KW - SARS-CoV-2 KW - Structural protein KW - Vaccine SP - 132 EP - 132 JF - Infectious diseases of poverty JO - Infect Dis Poverty VL - 9 IS - 1 N2 - BACKGROUND: Coronavirus disease 2019 (COVID-19) linked with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause severe illness and life-threatening pneumonia in humans. The current COVID-19 pandemic demands an effective vaccine to acquire protection against the infection. Therefore, the present study was aimed to design a multiepitope-based subunit vaccine (MESV) against COVID-19. METHODS: Structural proteins (Surface glycoprotein, Envelope protein, and Membrane glycoprotein) of SARS-CoV-2 are responsible for its prime functions. Sequences of proteins were downloaded from GenBank and several immunoinformatics coupled with computational approaches were employed to forecast B- and T- cell epitopes from the SARS-CoV-2 highly antigenic structural proteins to design an effective MESV. RESULTS: Predicted epitopes suggested high antigenicity, conserveness, substantial interactions with the human leukocyte antigen (HLA) binding alleles, and collective global population coverage of 88.40%. Taken together, 276 amino acids long MESV was designed by connecting 3 cytotoxic T lymphocytes (CTL), 6 helper T lymphocyte (HTL) and 4 B-cell epitopes with suitable adjuvant and linkers. The MESV construct was non-allergenic, stable, and highly antigenic. Molecular docking showed a stable and high binding affinity of MESV with human pathogenic toll-like receptors-3 (TLR3). Furthermore, in silico immune simulation revealed significant immunogenic response of MESV. Finally, MEV codons were optimized for its in silico cloning into the Escherichia coli K-12 system, to ensure its increased expression. CONCLUSION: The MESV developed in this study is capable of generating immune response against COVID-19. Therefore, if designed MESV further investigated experimentally, it would be an effective vaccine candidate against SARS-CoV-2 to control and prevent COVID-19. SN - 2049-9957 UR - https://www.unboundmedicine.com/medline/citation/32938504/Reverse_vaccinology_assisted_designing_of_multiepitope_based_subunit_vaccine_against_SARS_CoV_2_ L2 - https://idpjournal.biomedcentral.com/articles/10.1186/s40249-020-00752-w DB - PRIME DP - Unbound Medicine ER -